{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:29:51Z","timestamp":1790774991092,"version":"4.1.0"},"reference-count":78,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Resp Res"],"accepted":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>The major cause of mortality in people with cystic fibrosis (pwCF) is progressive lung disease characterised by acute and chronic infections, the accumulation of mucus, airway inflammation, structural damage and pulmonary exacerbations. The prevalence of <jats:italic>Pseudomonas aeruginosa<\/jats:italic> rises rapidly in the teenage years, and this organism is the most common cause of chronic lung infection in adults with cystic fibrosis (CF). It is associated with an accelerated decline in lung function and premature death. New <jats:italic>P. aeruginosa<\/jats:italic> infections are treated with antibiotics to eradicate the organism, while chronic infections require long-term inhaled antibiotic therapy. The prevalence of <jats:italic>P. aeruginosa<\/jats:italic> infections has decreased in CF registries since the introduction of CF transmembrane conductance regulator modulators (CFTRm), but clinical observations suggest that chronic <jats:italic>P. aeruginosa<\/jats:italic> infections usually persist in patients receiving CFTRm. This indicates that pwCF may still need inhaled antibiotics in the CFTRm era to maintain long-term control of <jats:italic>P. aeruginosa<\/jats:italic> infections. Here, we provide an overview of the changing perceptions of <jats:italic>P. aeruginosa<\/jats:italic> infection management, including considerations on detection and treatment, the therapy burden associated with inhaled antibiotics and the potential effects of CFTRm on the lung microbiome. We conclude that updated guidance is required on the diagnosis and management of <jats:italic>P. aeruginosa<\/jats:italic> infection. In particular, we highlight a need for prospective studies to evaluate the consequences of stopping inhaled antibiotic therapy in pwCF who have chronic <jats:italic>P. aeruginosa<\/jats:italic> infection and are receiving CFTRm. This will help inform new guidelines on the use of antibiotics alongside CFTRm.<\/jats:p>","DOI":"10.1136\/bmjresp-2023-002049","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T11:25:22Z","timestamp":1714735522000},"page":"e002049","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Considerations for the use of inhaled antibiotics for <i>Pseudomonas aeruginosa<\/i> in people with cystic fibrosis receiving CFTR modulator therapy"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04509050","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9, Institut Cochin, Inserm U1016, Paris, France"},{"name":"Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique H\u00f4pitaux de Paris, Paris, France"},{"name":"ERN-lung CF Network, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Ballmann","sequence":"additional","affiliation":[{"name":"Kinder- und Jugendklinik der Universit\u00e4tsmedizin Rostock, Rostock, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Drevinek","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Heijerman","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, University Children's Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen G","family":"Mainz","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Brandenburg (MHB) University, Klinikum Westbrandenburg, Brandenburg an der Havel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peckham","sequence":"additional","affiliation":[{"name":"Leeds Institute of Medical Research, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J","family":"Plant","sequence":"additional","affiliation":[{"name":"Cork Adult Cystic Fibrosis Centre, Cork University Hospital, University College, Cork, Republic of Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schwarz","sequence":"additional","affiliation":[{"name":"HMU-Health and Medical University Potsdam, Internal Medicine and Pneumology, Clinic Westbrandenburg, Division of Cystic Fibrosis, CF Center Westbrandenburg, Campus Potsdam, Potsdam, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Taccetti","sequence":"additional","affiliation":[{"name":"Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Department of Paediatric Medicine, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Smyth","sequence":"additional","affiliation":[{"name":"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"2025083112214812000_11.1.e002049.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1300109"},{"key":"2025083112214812000_11.1.e002049.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.009"},{"key":"2025083112214812000_11.1.e002049.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2015.09.002"},{"key":"2025083112214812000_11.1.e002049.4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jpids\/piac052","article-title":"Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection","volume":"11","author":"Blanchard","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025083112214812000_11.1.e002049.5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1055\/s-0039-1698464","article-title":"Microbiology of cystic fibrosis airway disease","volume":"40","author":"Blanchard","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"2025083112214812000_11.1.e002049.6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-0042-1758732","article-title":"Microbial epidemiology of the cystic fibrosis airways: past, present, and future","volume":"44","author":"Thornton","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2025083112214812000_11.1.e002049.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201507-1281OC"},{"key":"2025083112214812000_11.1.e002049.8","unstructured":"Zolin A , Orenti A , Jung A . ECFSPR annual report 2021. 2023. Available: https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports"},{"key":"2025083112214812000_11.1.e002049.9","unstructured":"Cystic Fibrosis Foundation . Patient Registry annual data report. September 2022. 2021. Available: https:\/\/www.cff.org\/medical-professionals\/patient-registry"},{"key":"2025083112214812000_11.1.e002049.10","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00019-18","article-title":"Epidemiology, biology, and impact of clonal Pseudomonas aeruginosa infections in cystic fibrosis","volume":"31","author":"Parkins","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2025083112214812000_11.1.e002049.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2020.10.008"},{"key":"2025083112214812000_11.1.e002049.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)05169-0"},{"key":"2025083112214812000_11.1.e002049.13","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"6","author":"Langton Hewer","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083112214812000_11.1.e002049.14","article-title":"Inhaled anti-Pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025083112214812000_11.1.e002049.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.02.006"},{"key":"2025083112214812000_11.1.e002049.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201207-1160OE"},{"key":"2025083112214812000_11.1.e002049.17","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201404-166OC"},{"key":"2025083112214812000_11.1.e002049.18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/antibiotics12030484","article-title":"Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis","volume":"12","author":"Li","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2025083112214812000_11.1.e002049.19","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade2216"},{"key":"2025083112214812000_11.1.e002049.20","unstructured":"European Medicines Agency . Kaftrio summary of product characteristics. 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kaftrio-epar-product-information_en.pdf"},{"key":"2025083112214812000_11.1.e002049.21","unstructured":"Food and Drug Administration . Trikafta highlights of prescribing information. 2023. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217660s000lbl.pdf"},{"key":"2025083112214812000_11.1.e002049.22","unstructured":"European Medicines Agency . Kalydeco summary of product characteristics. 2023. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kalydeco-epar-product-information_en.pdf"},{"key":"2025083112214812000_11.1.e002049.23","unstructured":"Food and Drug Administration . Kalydeco highlights of prescribing information. 2023. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203188s038lbl.pdf"},{"key":"2025083112214812000_11.1.e002049.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"2025083112214812000_11.1.e002049.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2025083112214812000_11.1.e002049.26","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083112214812000_11.1.e002049.27","doi-asserted-by":"crossref","unstructured":"Daines CL , Tullis E , Costa S , et al . Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508Del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J 2023;62. doi:10.1183\/13993003.02029-2022","DOI":"10.1183\/13993003.02029-2022"},{"key":"2025083112214812000_11.1.e002049.28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025083112214812000_11.1.e002049.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0392OC"},{"key":"2025083112214812000_11.1.e002049.30","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jcf.2022.08.014","article-title":"Availability of CFTR modulators in countries of Eastern Europe: the reality in 2022","volume":"21","author":"Drevinek","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2025083112214812000_11.1.e002049.32","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor \u2013 tezacaftor \u2013 ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"2025083112214812000_11.1.e002049.33","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03148-21","article-title":"Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections","volume":"12","author":"Durfey","year":"2021","journal-title":"mBio"},{"key":"2025083112214812000_11.1.e002049.34","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0154-2022"},{"key":"2025083112214812000_11.1.e002049.35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2025083112214812000_11.1.e002049.36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcf.2021.08.035","article-title":"Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network","volume":"20","author":"Ong","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17476348.2023.2267427","article-title":"Adherence to inhaled antibiotics in people with cystic fibrosis: insights from a virtual patient advisory board","volume":"17","author":"Gambazza","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"2025083112214812000_11.1.e002049.38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/17476348.2022.2057951","article-title":"The use of tobramycin for Pseudomonas aeruginosa: a review","volume":"16","author":"Fiel","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"2025083112214812000_11.1.e002049.39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.40","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2147\/PPA.S211769","article-title":"Adherence to long-term therapies in cystic fibrosis: a French cross-sectional study linking prescribing, dispensing, and hospitalization data","volume":"13","author":"Rouz\u00e9","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2025083112214812000_11.1.e002049.41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s10880-018-9598-z","article-title":"Identifying factors that facilitate treatment adherence in cystic fibrosis: qualitative analyses of interviews with parents and adolescents","volume":"26","author":"Nicolais","year":"2019","journal-title":"J Clin Psychol Med Settings"},{"key":"2025083112214812000_11.1.e002049.42","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21195"},{"key":"2025083112214812000_11.1.e002049.43","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"key":"2025083112214812000_11.1.e002049.44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025083112214812000_11.1.e002049.45","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201004-0643OC"},{"key":"2025083112214812000_11.1.e002049.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2003.09.026"},{"key":"2025083112214812000_11.1.e002049.47","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219086"},{"key":"2025083112214812000_11.1.e002049.48","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2025083112214812000_11.1.e002049.49","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/MCP.0000000000000616","article-title":"Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis","volume":"25","author":"Zemanick","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2025083112214812000_11.1.e002049.50","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00268002"},{"key":"2025083112214812000_11.1.e002049.51","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(18)30171-1","article-title":"The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial","volume":"6","author":"Ronchetti","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025083112214812000_11.1.e002049.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36244-2"},{"key":"2025083112214812000_11.1.e002049.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.006"},{"key":"2025083112214812000_11.1.e002049.54","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V"},{"key":"2025083112214812000_11.1.e002049.55","doi-asserted-by":"crossref","unstructured":"Burgel P-R , Southern KW , Addy C , et al . Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros 2024. doi:10.1016\/j.jcf.2024.01.005","DOI":"10.1016\/j.jcf.2024.01.005"},{"key":"2025083112214812000_11.1.e002049.56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcf.2019.08.014","article-title":"A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials","volume":"19","author":"Taccetti","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.57","doi-asserted-by":"crossref","first-page":"036013","DOI":"10.1088\/1752-7155\/10\/3\/036013","article-title":"Do linear logistic model analyses of volatile biomarkers in exhaled breath of cystic fibrosis patients reliably indicate Pseudomonas aeruginosa infection","volume":"10","author":"\u0160pan\u011bl","year":"2016","journal-title":"J Breath Res"},{"key":"2025083112214812000_11.1.e002049.58","doi-asserted-by":"crossref","unstructured":"Dobi\u00e1\u0161 R , \u0160kr\u00edba A , Pluh\u00e1 T , et al . Noninvasive combined diagnosis and monitoring of Aspergillus and Pseudomonas infections: proof of concept. J Fungi (Basel) 2021;7. doi:10.3390\/jof7090730","DOI":"10.3390\/jof7090730"},{"key":"2025083112214812000_11.1.e002049.59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jcf.2020.10.005","article-title":"The virtual CF clinic: implications for Sputum Microbiology","volume":"20","author":"Moore","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.60","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jcf.2016.01.001","article-title":"Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis","volume":"15","author":"Zampoli","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.61","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2008.104711"},{"key":"2025083112214812000_11.1.e002049.62","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(13)00150-1","article-title":"Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis","volume":"12","author":"Aan\u00e6s","year":"2013","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.06.001"},{"key":"2025083112214812000_11.1.e002049.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.12.003"},{"key":"2025083112214812000_11.1.e002049.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.01.005"},{"key":"2025083112214812000_11.1.e002049.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2013.09.004"},{"key":"2025083112214812000_11.1.e002049.67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2021.07.020","article-title":"Comparing encounter-based and annualized chronic Pseudomonas infection definitions in cystic fibrosis","volume":"21","author":"Rosenfeld","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.68","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.04083-22","article-title":"Mutual effects of single and combined CFTR modulators and bacterial infection in cystic fibrosis","volume":"11","author":"Cigana","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2025083112214812000_11.1.e002049.69","doi-asserted-by":"crossref","first-page":"548613","DOI":"10.3389\/fcimb.2021.548613","article-title":"Changes in the cystic fibrosis airway microbiome in response to CFTR modulator therapy","volume":"11","author":"Yi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2025083112214812000_11.1.e002049.70","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcf.2019.07.008","article-title":"The impact of CFTR modulator therapies on CF airway microbiology","volume":"19","author":"Rogers","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.71","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220100"},{"key":"2025083112214812000_11.1.e002049.72","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2025083112214812000_11.1.e002049.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"2025083112214812000_11.1.e002049.74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2025083112214812000_11.1.e002049.75","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1513\/AnnalsATS.202208-684OC","article-title":"Effects of lumacaftor\/ivacaftor on cystic fibrosis disease progression in children 2 through 5 years of age homozygous for F508del-CFTR: a phase 2 placebo-controlled clinical trial","volume":"20","author":"Stahl","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2025083112214812000_11.1.e002049.76","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jcf.2022.10.005","article-title":"New concepts in antimicrobial resistance in cystic fibrosis respiratory infections","volume":"21","author":"Drevinek","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025083112214812000_11.1.e002049.77","unstructured":"BiomX . BiomX reports second quarter 2023 financial results and provides business update, August 2023. Available: https:\/\/ir.biomx.com\/news-events\/press-releases\/detail\/92\/biomx-reports-second-quarter-2023-financial-results-and"},{"key":"2025083112214812000_11.1.e002049.78","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"}],"container-title":["BMJ Open Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjresp-2023-002049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T19:22:00Z","timestamp":1756668120000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopenrespres.bmj.com\/lookup\/doi\/10.1136\/bmjresp-2023-002049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bmjresp-2023-002049"],"URL":"https:\/\/doi.org\/10.1136\/bmjresp-2023-002049","relation":{},"ISSN":["2052-4439"],"issn-type":[{"value":"2052-4439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}